Frontotemporal lobar degeneration: clinical and pathological relationships.

Area of Science:

• Neuroscience
• Neuropathology
• Genetics

Background:

• Frontotemporal lobar degeneration (FTLD) is a diverse group of neurodegenerative diseases.
• Clinical presentation is often considered a weak indicator of the underlying brain pathology.
• Recent advancements in immunohistochemistry allow for a re-evaluation of this assumption.

Purpose of the Study:

• To investigate the relationship between clinical syndromes of FTLD and their histopathological characteristics.
• To determine if clinical phenotype can predict the topographical distribution of brain atrophy and specific protein markers.

Main Methods:

• Pathological brain samples from 79 FTLD patients were classified based on atrophy patterns and immunohistochemistry, independent of clinical diagnosis.
• Clinical syndromes included frontotemporal dementia (FTD), FTD with motor neurone disease (FTD/MND), progressive non-fluent aphasia (PNFA), semantic dementia (SD), and progressive apraxia (PAX).
• Immunohistochemistry was used to detect tau, ubiquitin, TDP-43, and genetic mutations (MAPT, PGRN).

Main Results:

• Significant correlations were found between clinical syndromes and atrophy patterns (e.g., frontal/temporal in FTD, perisylvian in PNFA).
• Tau pathology was present in FTD and PAX, absent in FTD/MND and SD. Ubiquitin and TDP-43 positivity was observed in FTD/MND, SD, and PNFA.
• Specific subtypes of FTLD-U (ubiquitin-positive, TDP-43-positive) were associated with distinct pathological inclusions. MAPT and PGRN mutations were linked to specific FTD subtypes.

Conclusions:

• Clinical phenotype is a reliable predictor of both the topographical distribution of brain atrophy and the immunohistochemical characteristics in FTLD.
• Refined clinical and pathological phenotyping is crucial for advancing the understanding of FTLD and its molecular basis.